CN109125377A - Application of watermelon young fruit and jaboticaba young fruit in preparation of pharmaceutical composition for regulating and controlling genes - Google Patents
Application of watermelon young fruit and jaboticaba young fruit in preparation of pharmaceutical composition for regulating and controlling genes Download PDFInfo
- Publication number
- CN109125377A CN109125377A CN201810542075.0A CN201810542075A CN109125377A CN 109125377 A CN109125377 A CN 109125377A CN 201810542075 A CN201810542075 A CN 201810542075A CN 109125377 A CN109125377 A CN 109125377A
- Authority
- CN
- China
- Prior art keywords
- young fruit
- fruit extract
- melon young
- melon
- medical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 132
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 title claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 4
- 230000001276 controlling effect Effects 0.000 title claims description 5
- 244000170059 Myrciaria cauliflora Species 0.000 title abstract 4
- 235000006992 Myrciaria cauliflora Nutrition 0.000 title abstract 4
- 244000241235 Citrullus lanatus Species 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 91
- 241000219109 Citrullus Species 0.000 claims abstract description 55
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 40
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims abstract description 28
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims abstract description 24
- 102100033902 Endothelin-1 Human genes 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 21
- 108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 21
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 claims abstract description 14
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims abstract description 14
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims abstract description 14
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims abstract description 13
- 229940096397 interleukin-8 Drugs 0.000 claims abstract description 13
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims abstract description 10
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 claims abstract description 10
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims abstract description 10
- 230000036772 blood pressure Effects 0.000 claims abstract description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 8
- 101800004490 Endothelin-1 Proteins 0.000 claims abstract description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 8
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 8
- 239000003114 blood coagulation factor Substances 0.000 claims abstract description 8
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 101710107117 Serine protease inhibitor 1 Proteins 0.000 claims abstract description 3
- 241000219112 Cucumis Species 0.000 claims description 69
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 69
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 69
- 102100036537 von Willebrand factor Human genes 0.000 claims description 20
- 238000002965 ELISA Methods 0.000 claims description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 230000033228 biological regulation Effects 0.000 claims description 10
- 230000019522 cellular metabolic process Effects 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 7
- 102000030168 Endothelin A Receptor Human genes 0.000 claims description 7
- 108010090549 Endothelin A Receptor Proteins 0.000 claims description 7
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims description 7
- 108010000499 Thromboplastin Proteins 0.000 claims description 7
- 102000002262 Thromboplastin Human genes 0.000 claims description 7
- 230000003255 anti-acne Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 229960001134 von willebrand factor Drugs 0.000 claims description 6
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 4
- 101150050263 ICAM1 gene Proteins 0.000 claims description 4
- 101150031207 NOS3 gene Proteins 0.000 claims description 4
- -1 PALT) Proteins 0.000 claims description 4
- 101710115194 Protease inhibitor 1 Proteins 0.000 claims description 4
- 101150045640 VWF gene Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003828 downregulation Effects 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000036576 dermal application Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 claims 3
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract description 11
- 210000002510 keratinocyte Anatomy 0.000 abstract description 8
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 206010000496 acne Diseases 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 208000027276 Von Willebrand disease Diseases 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 229920000832 Cutin Polymers 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000009831 Citrullus lanatus Nutrition 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 102000052624 human CXCL8 Human genes 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical class C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
- 229950006240 hydrocortisone succinate Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of plant extracts, in particular to an application of watermelon young fruit and jaboticaba young fruit in preparing a medicinal composition for regulating genes, wherein the composition containing the watermelon young fruit extract, the jaboticaba young fruit extract or a combination of the watermelon young fruit extract and the jaboticaba young fruit extract can regulate and control nitric oxide synthase 3(NOS3) and von willebrand disease factor (vWF) genes upwards and regulate and control the expression quantity of genes of interleukin-8 (IL-8), endothelin 1(EDN1), tissue Plasminogen Activator (PALT), human blood coagulation factor (F3), serine protease inhibitor 1(SERPINE1) and intercellular adhesion molecule 1(ICAM1) downwards, so that the keratinocyte metabolism is promoted, the secretion of the interleukin-8 is inhibited, and the effects of resisting inflammation and acne and reducing blood pressure and blood fat are finally achieved.
Description
Technical field
The present invention relates to plant extract fields, and the present invention is more particularly directed to a kind of water melon young fruits and Garbo melon young fruit for making
The purposes of the medical composition of standby controlling gene.
Background technique
Modern life is in the case where hurry green, pressure environment, breakfast, lunch and dinner are irregular or eat processed food, on skin quality
Face the excessively vigorous problem of maximum sebaceous glands, and male's skin can often have more greases, especially more than 25 than women skin
Year old or more have enlarged pores oily skin, for a long time exposure under ultraviolet light, extended trip, habit evening sleep, have and drink and coffee
The habit of coffee, smoking or the group to work under cold air environment under secondhand smoke environment and for a long time, often have skin greasing,
The coarse blocking of pore generates the problems such as acne.
Meanwhile as the growth cholesterol at age can be piled up in blood vessel, inner skin cell function defect is caused, changes endothelium
Cell script anticoagulation, the characteristic of anti-inflammatory and narrowed blood vessels are easy to cause the diseases such as hypertension, artery sclerosis.
Therefore, above-mentioned these problems are faced, people must make great efforts just skin and physical function can be made to push away by the maintenance day after tomorrow
Slow aging, or even return the body of young skin quality and health.In recent years, to reach the demand that people postpone aging, on the market not
Disconnection sending is various either to utilize the product wiped, smear or taken orally.However, those products are to require to reach special-effect, and add
Enter excessive carcinogenic chemical substance or Environmental Hormone, makes consumer's use under unwitting situation that can injure skin effects strong
The ingredient of health.Therefore, the modern times for stressing natural health, in whitening product addition containing natural effective ingredient, be one by
Gradually popular trend.
Summary of the invention
It is used to prepare regulation in view of this, the present invention provides a kind of melon young fruit of Curcurbitaceae and is situated between white element -8
(interleukin-8, IL-8), nitricoxide synthase 3 (nitric oxide synthase 3, NOS3), Endothelin receptor A
(endothelin 1, EDN1), tissue-type plasminogen activator (tissue type-plasminogen activator,
PALT), vWF ELISA (von Willebrand factor, vWF), mankind's coagulation factor (Homo sapiens
Coagulation factor III (tissue factor), F3), 1 (serine of serine stretch protein ferment inhibitor
Protease inhibitor 1, SERPINE1) and Intercellular surface adhesion molecule-1 (intercellular adhesion
Molecule 1, ICAM1) gene performance amount medical composition purposes, wherein NOS3 and vWF gene is to regulate and control upwards,
EDN1, PLAT, F3, SERPINE1, IL-8 and ICAM1 gene are to down regulation；And the melon young fruit of the Curcurbitaceae be selected from by
Group composed by one water melon young fruit extract, a Garbo melon young fruit extract and combinations thereof.
The present invention separately provides a kind of melon young fruit of Curcurbitaceae and is used to prepare the medical composition for promoting horn cell metabolism
Purposes, wherein the melon young fruit of the Curcurbitaceae is selected from by a water melon young fruit extract, a Garbo melon young fruit extract and its group
Group composed by closing.
The present invention, which provides a kind of melon young fruit of Curcurbitaceae again and is used to prepare, to reduce blood pressure and the use of the medical composition of blood lipid
On the way, wherein the melon young fruit of the Curcurbitaceae is selected from by a water melon young fruit extract, a Garbo melon young fruit extract and combinations thereof
Composed group.
In one embodiment of this invention, wherein the medical composition have promote horn cell metabolism, anti-inflammatory and
The effect of anti-acne.
In one embodiment of this invention, wherein the medical composition can inhibit -8 (interleukin-8, the IL- of white element that are situated between
8) it secretes.
In one embodiment of this invention, wherein the medical composition has the effect of reducing blood pressure and blood lipid.
In one embodiment of this invention, wherein the melon young fruit extract of the Curcurbitaceae be with water, alcohols, aqueous alcohols or
A combination thereof is as an extractant, and the volume ratio of the extractant and the melon young fruit of Curcurbitaceae is 2~20:1~5.
In one embodiment of this invention, wherein the medical composition is for regulating and controlling -8 (interleukin- of white element that are situated between
8, IL-8), nitricoxide synthase 3 (nitric oxide synthase 3, NOS3), Endothelin receptor A (endothelin 1,
EDN1), tissue-type plasminogen activator (tissue type-plasminogen activator, PALT), vascular blood friend
Cause of disease (von Willebrand factor, vWF), mankind's coagulation factor (Homo sapiens coagulation
Factor III (tissue factor), F3), (the serine protease inhibitor of serine stretch protein ferment inhibitor 1
1, SERPINE1) and Intercellular surface adhesion molecule-1 (intercellular adhesion molecule 1, ICAM1) gene
Performance amount, and NOS3 and vWF gene is to regulate and control upwards, EDN1, PLAT, F3, SERPINE1, IL-8 and ICAM1 gene are downward
Regulation.
In one embodiment of this invention, wherein the medical composition further includes a pharmaceutically acceptable carrier.
In one embodiment of this invention, wherein the medical composition is given in the form of oral or dermal application.
Therefore, the composition of the invention containing water melon young fruit extract, Garbo melon young fruit extract or combinations thereof, can be saturating
Cross regulation nitricoxide synthase 3 (nitric oxide synthase 3, NOS3) and vWF ELISA (von upwards
Willebrand factor, vWF) gene, and be situated between white element -8 (interleukin-8, IL-8), Endothelin receptor A to down regulation
(endothelin 1, EDN1), tissue-type plasminogen activator (tissue type-plasminogen activator,
PALT), mankind's coagulation factor (Homo sapiens coagulation factor III (tissue factor), F3), silk
Propylhomoserin Pepsin inhibitor 1 (serine protease inhibitor 1, SERPINE1) and Intercellular surface adhesion molecule-1
The performance amount of (intercellular adhesion molecule 1, ICAM1) gene, so promote horn cell metabolism with
And inhibit white -8 secretion of element that is situated between, it is finally reached anti-inflammatory, anti-acne and reduces blood pressure, the effect of blood lipid.Therefore of the invention contain
There is the composition of water melon young fruit extract, Garbo melon young fruit extract or combinations thereof to can be used for preparing the purposes of medical composition.
Embodiments of the present invention are further illustrated below in conjunction with schema, and following cited embodiments are to illustrate
The present invention, the range being not intended to limit the invention is any to be familiar with this those skilled in the art, is not departing from the spirit and scope of the present invention
It is interior, when can do it is a little change and retouch, therefore protection scope of the present invention when regard appended claims institute's defender as
It is quasi-.
Detailed description of the invention
Fig. 1 is the data of the promotion keratinocyte hyperplasia of water melon young fruit extract of the invention or Garbo melon young fruit extract
Figure.Compared to p < 0.001 control group * p < 0.05, * * p < 0.01, * * *.
Fig. 2 inspires inflammatory cell hormone IL-8 for the reduction of water melon young fruit extract of the invention or Garbo melon young fruit extract
The datagram of generation.Compared to p < 0.01 control group * p < 0.05, * *.
Fig. 3 is water melon young fruit extract of the invention or Garbo melon young fruit extract to the vasodilative nitric oxide of regulation
Endothelin receptor A that synthase 3 (nitric oxide synthase 3, NOS3) and modulating vascular are shunk (endothelin 1,
EDN1 the datagram of gene performance).Compared to p < 0.01 control group * p < 0.05, * *.
Fig. 4 is the vascular blood that water melon young fruit extract of the invention or Garbo melon young fruit extract decompose regulation thrombus
The friendly cause of disease sub (von Willebrand factor, vWF) and regulation inhibit the tissue-type plasminogen activator of angiogenesis
(tissue type-plasminogen activator, PALT), mankind's coagulation factor (Homo sapiens
Coagulation factor III (tissue factor), F3) and 1 (serine of serine stretch protein ferment inhibitor
Protease inhibitor 1, SERPINE1) gene performance datagram.Compared to control group * p < 0.05, * * p <
0.01。
Fig. 5 is that water melon young fruit extract of the invention or Garbo melon young fruit extract inspire the scorching white element -8 of factor Jie to regulation
(interleukin-8, IL-8) and Intercellular surface adhesion molecule-1 (intercellular adhesionmolecule 1,
ICAM1 the datagram of gene performance).Compared to p < 0.01 control group * p < 0.05, * *.
Specific embodiment
The present invention provides a kind of composition containing the melon young fruit of Curcurbitaceae, is extracted with 50 to 100 DEG C of temperature
It takes, and water melon young fruit and Garbo melon young fruit is extracted and are centrifuged and obtained respectively with solvent, wherein the extractant is water, alcohol
Class, aqueous alcohols or combinations thereof.The present invention carries out water melon young fruit extract of the invention using cellular proliferation agents set group or praises
Analysis of the precious melon young fruit extract to horn cell metabolism is promoted, and exempted from using human interleukin 8 (IL-8/CXCL8) ferment
Epidemic disease analytic approach (enzyme-linked immunosorbent assay, ELISA) analysis detection reagent set group carries out the present invention
The analysis to the rejection ability for inspiring inflammatory cell hormone IL-8 of water melon young fruit extract or Garbo melon young fruit extract, and via
The detection of gene performance amount carries out water melon young fruit extract or Garbo melon young fruit extract of the invention to vascular endothelial cell gene
Regulation analysis, to confirm the composition of the invention containing water melon young fruit extract or Garbo melon young fruit extract, can promote
Horn cell metabolism and the white element -8 of inhibition Jie are secreted, and are finally reached anti-inflammatory, anti-acne and are reduced blood pressure, the effect of blood lipid
Fruit.
The preparation method of the melon young fruit extract of the Curcurbitaceae of the invention of embodiment 1
Watermelon (Citrullus lanatus), Gu claim cold melon, are a kind of plant or its fruit of Curcurbitaceae Citrullus.It is former
Africa is originated in, is a kind of dicotyledonous flowering plant, for shape as tendril, leaf is in featheriness.The fruit that it is born is pseudocarp, and
Belong to one kind that botanist is known as false berry.Fruit rinds are smooth, in green or yellow and have bottle-green decorative pattern, fruit flesh is more
Juice is red or yellow.
Garbo melon (Citrullus lanatus (Thunb.) Matsum et Nakai) is TaiWan, China early stage watermelon product
One of kind, original name Garbo soldier's melon, pioneer's kind of orange flesh, only Penghu County has Economical cultivation and history is long-drawn-out for Taiwan
Long；Because matter is crisp and flavour, the deep favor by Penghu resident and tourist, therefore its output value and peasant's cultivation wish are high,
Early have become the Special Agriculture Product of the high economic value in Penghu area.
In one embodiment of this invention, water melon young fruit or Garbo melon young fruit are after cleaning, by water, alcohols or aqueous alcohols
Or combinations thereof extractant respectively with water melon young fruit or Garbo melon young fruit with the volume ratio of 2~20:1~5, in 50 DEG C after homogeneous
Extraction 0.5 to 3 hour each thick extract for obtaining water melon young fruit, Garbo melon young fruit is carried out to 100 DEG C；Room is cooled to after extraction
The thick extract is centrifuged by temperature, the supernatant after taking centrifugation；By the supernatant with 400mech strainer filtering to be filtered
Liquid；Finally the filtrate is carried out to be concentrated under reduced pressure to give water melon young fruit extract or Garbo melon young fruit extraction of the invention in 45~70 DEG C
Take object.Wherein the water melon young fruit is defined as young fruit in 3 weeks, and melon meat is white；Garbo melon young fruit is defined as young fruit in 20 days, and melon meat is white；
And include the full melon of melon skin, the embodiment of the present invention is with full melon while to be extracted.
The effect for promoting horn cell metabolism of the water melon young fruit extract of the invention of embodiment 2 or Garbo melon young fruit extract
Fruit
The present invention carries out the analysis of promotion horn cell (keratinocytes) metabolism.It is collected by Unite States Standard biology product
Buy human keratinocyte (number PCS-200- in center (American Type Culture Collection, ATCC)
010TM).By the cell culture in skin minimal medium (dermal cell basal medium) (ATCC, the U.S., number
PCS-200-030TM), and keratinocyte growth factor (ATCC, the U.S., number PCS-200-040TM) is added, wherein including:
The 0.5ng/mL recombined human of the 0.4% Niu Chuiti extract (bovine pituitary extract, BPE) of 2.0mL, 0.5mL
Transforming growth factor α (rh TGF- α), the 6mM L-Glutamine (L-glutamine) of 15.0mL, 0.5mL 100ng/mL half
5mg/mL rh-insulin (the rh of succinic acid cortisol (hydrocortisone hemisuccinate), 0.5mL
Insulin), the 5mg/mL transferrins (apo-Transferrin) of the 1.0mM and 0.5mL of 0.5mL.
(Roche company, Switzerland, number 11647229001) is analyzed using cellular proliferation agents set group.Firstly,
Each hole is inoculated with 6,000 horn cell in 96 hole culture plates, is incubated at 37 DEG C 2 hours with above-mentioned culture medium；Hole point
The Garbo 0.25mg/mL melon young fruit extract that 100 μ L are not added, Garbo ripe fruit extract are (with 1 same procedure system of embodiment
It is standby) and water melon young fruit extract as experimental group；The another 50ng/mL epidermal growth factor (Epidermal that 100 μ L are added
Growth factor, EGF) as a control group；And the culture medium not add any ingredient is as control group, each hole later
100 μM of bromodeoxyuridines (Bromodeoxyuridine, BrdU) of 10 μ L are added in hole, and it is small to continue culture 24 under the conditions of same
When, it is inlaid into the content of DNA using BrdU, detects hyperplasia situation.Culture medium is removed, consolidating for 200 μ L is added in each hole
Determine liquid (FixDenat) to react 30 minutes at room temperature, removes fixer and with phosphate buffered saline (Phosphate
Buffered saline, PBS) cleaning is once.Anti- bromodeoxyuridine-peroxidase of 100 μ L is added in each hole
(anti-BrdU-POD) 90 minutes are stood at room temperature, recognizes the anti-BrdU for marking peroxidase (peroxidase)
BrdU.After removing anti-BrdU-POD, three times with 200 to 300 μ L PBS cleaning, matrix solution is added in last each hole
(TMB) make to react colour generation, after standing about 5 to 30 minutes at room temperature, the 1M H of 25 μ L is added2SO4Reaction is terminated, and is utilized immune
The light absorption value that enzymatic analysis instrument (ELISA reader) (Bio Tek company, the U.S.) measures its 450nm, is counted with Excel
Analysis.
The effect that water melon young fruit extract or Garbo melon young fruit extract of the invention is metabolized promotion horn cell
Experimental result such as Fig. 1, after the processing of water melon young fruit extract, Garbo melon young fruit extract and Garbo ripe fruit, cutin is thin
Born of the same parents' hyperplasia obviously increases.Compared to notified promote keratinocyte hyperplasia epidermal growth factor keratinocyte hyperplasia as a result,
Water melon young fruit extract about increases by 10%, and Garbo melon young fruit extract about increases by 5%, and Garbo ripe fruit extract and epidermis are raw
The keratinocyte hyperplasia of the long factor is similar.Therefore, water melon young fruit extract of the invention, Garbo melon young fruit extract or its group
Conjunction has effects that excellent promotion keratinocyte hyperplasia, can effectively be metabolized horn cell.
The water melon young fruit extract of the invention of embodiment 3 or Garbo melon young fruit extract inhibit the white element -8 that is situated between
(interleukin-8, IL-8) secretion
Since -8 (interleukin-8, IL-8) of the white element of known Jie have the function of inflammatory response, therefore, this hair
Bright further detection water melon young fruit extract or Garbo melon young fruit extract are to the rejection ability for inspiring inflammatory cell hormone IL-8.
Using the horn cell such as previous embodiment 2, the present invention utilizes (IL-8/CXCL8) ELISA of human interleukin 8 points
Analysis detection reagent set group (R&D systems company, the U.S.) is analyzed.Firstly, each containing 500 μ in 24 hole culture plates
Inoculation 5 × 10 in the hole of the above-mentioned culture medium of L4A horn cell is incubated at 37 DEG C 24 hours；Carefully do not interfering attachment
Culture medium is removed in the case where cell, later each hole be separately added into 120 μ L the Garbo 0.25mg/mL melon young fruit extract,
Garbo ripe fruit extract using or water melon young fruit extract as experimental group；And not add any ingredient and be not exposed to ultraviolet
The culture medium of line is separately exposed under ultraviolet radiation as a control group with not adding the culture medium of any ingredient as control group,
Each group is in triplicate.Then cell is exposed under 300mJ ultraviolet light (UVB) radiation 24 hours at 37 DEG C, is received respectively
Collect the cell suspending liquid of 120 μ L.
The Mei Gekong into 96 hole ELISA disks is added in the capture antibody diluted with PBS (capture antibody)
The volume in hole is that 100 μ L are placed in 4 DEG C down toward overnight, and antibody is made to be adsorbed in 96 hole ELISA disks.It is slow with 200 μ L cleaning later
96 hole ELISA disks of fliud flushing (0.05%Tween 20 and PBS mixed liquor) cleaning three times, are added 300 μ L and block buffer (BSA
With PBS mixed liquor) it is placed at 37 DEG C 2 hours, to block non-specific absorption.Later with 200 μ L cleaning buffer solutions cleaning 96
Hole ELISA disk three times, is added 100 μ L detection antibody (detection antibody) and is placed at 37 DEG C 2 hours.Later with
200 μ L cleaning buffer solutions clean 96 hole ELISA disks three times, and 100 μ L streptavidin-HRP (streptavidin-HRP) are added
It places 20 minutes at room temperature.96 hole ELISA disks are cleaned three times with 200 μ L cleaning buffer solutions later, and it is molten that 100 μ L matrix are added
Liquid is placed 20 minutes at room temperature, adds 50 μ L stop baths to terminate reaction, and utilize immune enzymatic analysis instrument (ELISA
Reader) (Bio Tek company, the U.S.) measures the light absorption value of its 450nm, carries out t-test statistical analysis with Excel.
Water melon young fruit extract of the invention, Garbo melon young fruit extract or combinations thereof are for inhibiting -8 (IL-8) of white element that are situated between
The experimental result of the effect of secretion is as shown in Fig. 2, because the horn cell of aging is easy to be led to inflammatory response by environmental stimuli, phase
It is exposed to the IL-8 secretory volume under 300mJ ultraviolet light (UVB) radiation compared with cell, Garbo melon young fruit extract, which can reduce, inspires inflammation
Cytohormone IL-8 generates about 60%, and Garbo ripe fruit extract, which can reduce, inspires inflammatory cell hormone IL-8 generation about 33%, and
Water melon young fruit extract, which can reduce, inspires inflammatory cell hormone IL-8 generation about 26%.Therefore, water melon young fruit extract of the invention
Or Garbo melon young fruit extract the effect of capable of reducing the generation for inspiring inflammatory cell hormone IL-8, reaching anti-inflammatory.
The tune of the vascular endothelial cell gene of the water melon young fruit extract of the invention of embodiment 4 or Garbo melon young fruit extract
Control effect
By above-described embodiment water melon young fruit extract of the invention or Garbo melon young fruit extract can promote cutin be metabolized and
Anti-inflammatory, thus achieve the effect that anti-acne and pimples eventually.Due to the growth with the age, diet is abnormal, work and rest is bad etc.
It influences, cholesterol can be piled up in blood vessel, cause inner skin cell function defect, change endothelial cell script anticoagulation, anti-inflammatory
Characteristic and narrowed blood vessels be easy to cause the diseases such as hypertension, artery sclerosis.Vascular endothelial cell major function has regulation blood
The effect of immunocyte in pipe contraction, the generation of cytohormone and blood.Therefore, the present invention further detects water melon young fruit extraction
The influence of object or Garbo melon young fruit extract to related gene performance amount in vascular endothelial cell.
The present invention using Human umbilical vein endothelial cells (human umbilical vein endothelial Cells,
HUVEC it) (is saved by living resources and research center obtains, BCRC number H-UV001) and carry out vascular endothelial cell related gene
The experiment of performance amount.Each hole inoculation 1 × 10 first in 6 hole culture plates5A Human umbilical vein endothelial cells, to add 2mL
EC culture medium (Gibico company, the U.S., number M-200-500), be separately added into the Garbo the 0.03125mg/mL melon children of 100 μ L
Fruit extract, Garbo ripe fruit extract and water melon young fruit extract are as experimental group；And not add the training of any ingredient
Base is supported as control group, is cultivated 6 hours；Rear collection Human umbilical vein endothelial cells.Use RNA extraction agent group (Genemark
Company, the U.S.) the above-mentioned cell of extraction RNA, recycle reverse transcriptase ( III Reverse
Transcriptase) RNA reverse transcription is cDNA by (Invitrogen company, the U.S.), then uses KAPA
FAST qPCR reagent set (KAPA Biosystems company, the U.S.) measures target gene, wherein including the white element -8 that is situated between
(interleukin-8, IL-8), nitricoxide synthase 3 (nitric oxide synthase 3, NOS3), Endothelin receptor A
(endothelin 1, EDN1), tissue-type plasminogen activator (tissue type-plasminogen activator,
PALT), vWF ELISA (von Willebrand factor, vWF), mankind's coagulation factor (Homo sapiens
Coagulation factor III (tissue factor), F3), 1 (serine of serine stretch protein ferment inhibitor
Protease inhibitor 1, SERPINE1) and Intercellular surface adhesion molecule-1 (intercellular adhesion
Molecule 1, ICAM1) gene, it is analyzed with quantitative PCR apparatus.
Since vascular endothelial cell major function has modulating vascular to shrink, immunocyte in the generation of cytohormone and blood
Effect, as a result as shown in figure 3, by water melon young fruit extract effect, display can promote modulating vascular diastole NOS3's
Gene performance, and the gene performance that modulating vascular shrinks EDN1 can be reduced, indicate that the water melon young fruit extract of invention has
The effect of imitating into low blood pressure；As a result as shown in figure 4, water melon young fruit extract can promote the gene performance that thrombus decomposes vWF, and
It can achieve the gene performance for inhibiting angiogenesis PLAT, F3 and SERPINE1, indicate that water melon young fruit extract can promote thrombus
Thrombus is decomposed and reduces to generate；As a result as shown in figure 5, water melon young fruit extract can reduce promote inflammatory factor IL-8 and
The gene of ICAM1 shows, and indicates that water melon young fruit extract can reach the effect of anti-inflammatory.
In conclusion the composition of the invention containing water melon young fruit extract, Garbo melon young fruit extract or combinations thereof
It can be showed by the gene for promoting the good factor of vascular endothelial cell, such as NOS3 and vWF, and inhibit the endothelial cell blood vessel bad factor
Gene performance, such as EDN1, PLAT, F3, SERPINE1, IL-8 and ICAM1, thus reaches, so promote horn cell metabolism with
And inhibit white -8 secretion of element that is situated between, it is finally reached anti-inflammatory, anti-acne and reduces blood pressure, the effect of blood lipid.Therefore, the present invention contains
Having the composition of water melon young fruit extract or Garbo melon young fruit extract is a natural component, will not generate traditional artificial synthesis suppression
Side effect brought by preparation using the metabolism of conditioning skin cutin, anti-inflammatory, anti-acne and can reduce blood pressure, the doctor of blood lipid
Drug composition, the composition be with powdered, graininess, liquid, glue or paste presence, and its dosage form be with food, drink,
The form of drug, reagent or nutritional supplement provides, and can take orally or the mode of smearing is given.
Claims (10)
1. a kind of melon young fruit of Curcurbitaceae is used to prepare regulation Jie white element -8 (interleukin-8, IL-8), nitricoxide synthase
3 (nitric oxide synthase 3, NOS3), Endothelin receptor A (endothelin 1, EDN1), Plasminogen
Agent (tissue type-plasminogen activator, PALT), vWF ELISA (von Willebrand
Factor, vWF), mankind's coagulation factor (Homo sapiens coagulation factor III (tissue factor),
F3), serine stretch protein ferment inhibitor 1 (serine protease inhibitor 1, SERPINE1) and cell-cell adhesion
The purposes of the medical composition of the performance amount of molecule 1 (intercellular adhesion molecule 1, ICAM1) gene,
Wherein NOS3 and vWF gene is to regulate and control upwards, and EDN1, PLAT, F3, SERPINE1, IL-8 and ICAM1 gene are to down regulation；
And the melon young fruit of the Curcurbitaceae is to be selected to be made of a water melon young fruit extract, a Garbo melon young fruit extract and combinations thereof
Group.
2. purposes according to claim 1, which is characterized in that the medical composition have promote horn cell metabolism,
The effect of anti-inflammatory and anti-acne.
3. purposes according to claim 1, which is characterized in that the medical composition can inhibit the white element -8 that is situated between
(interleukin-8, IL-8) secretion.
4. purposes according to claim 1, which is characterized in that the medical composition, which has, to reduce blood pressure and the effect of blood lipid
Fruit.
5. a kind of melon young fruit of Curcurbitaceae is used to prepare the purposes for promoting the medical composition of horn cell metabolism, wherein the cucurbit
The melon young fruit of section is selected from the group as composed by a water melon young fruit extract, a Garbo melon young fruit extract and combinations thereof.
6. a kind of melon young fruit of Curcurbitaceae is used to prepare and reduces blood pressure and the purposes of the medical composition of blood lipid, wherein the Curcurbitaceae
Melon young fruit is selected from the group as composed by a water melon young fruit extract, a Garbo melon young fruit extract and combinations thereof.
7. according to claim 1, purposes described in any one of 5 and 6, which is characterized in that the melon young fruit extraction of Curcurbitaceae
Object is and the body of the extractant and the melon young fruit of Curcurbitaceae using water, alcohols, aqueous alcohols or combinations thereof as an extractant
Product is than being 2~20:1~5.
8. purposes according to claim 5 or 6, which is characterized in that the medical composition is for regulating and controlling the white element -8 that is situated between
(interleukin-8, IL-8), nitricoxide synthase 3 (nitric oxide synthase 3, NOS3), Endothelin receptor A
(endothelin 1, EDN1), tissue-type plasminogen activator (tissue type-plasminogen activator,
PALT), vWF ELISA (von Willebrand factor, vWF), mankind's coagulation factor (Homo sapiens
Coagulation factor III (tissue factor), F3), 1 (serine of serine stretch protein ferment inhibitor
Protease inhibitor 1, SERPINE1) and Intercellular surface adhesion molecule-1 (intercellular adhesion
Molecule 1, ICAM1) gene performance amount, and NOS3 and vWF gene is to regulate and control upwards, EDN1, PLAT, F3,
SERPINE1, IL-8 and ICAM1 gene are to down regulation.
9. according to claim 1, purposes described in any one of 5 and 6, which is characterized in that the medical composition further wraps
Containing a pharmaceutically acceptable carrier.
10. according to claim 1, purposes described in any one of 5 and 6, which is characterized in that the medical composition is with oral
Or the form of dermal application is given.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW106120420A TWI637747B (en) | 2017-06-19 | 2017-06-19 | A composition comprising young watermelon fruit extract, young chiapao melon fruit extract or combination thereof having functionality to regulate the gene expression of interleukin-8, nitric oxide synthase 3, endothelin 1, tissue type-plasminogen activa |
| TW106120420 | 2017-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125377A true CN109125377A (en) | 2019-01-04 |
Family
ID=64797520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810542075.0A Pending CN109125377A (en) | 2017-06-19 | 2018-05-30 | Application of watermelon young fruit and jaboticaba young fruit in preparation of pharmaceutical composition for regulating and controlling genes |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109125377A (en) |
| TW (1) | TWI637747B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151830A (en) * | 2019-05-27 | 2019-08-23 | 嘉兴市爵拓科技有限公司 | Water melon young fruit and Garbo melon young fruit are used to prepare the purposes of the medical composition of controlling gene |
| CN112007036A (en) * | 2019-05-29 | 2020-12-01 | 百岳特生物科技（上海）有限公司 | Application of compound and composition thereof in preparing medicine for relieving lung cell inflammation activity |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2242062A (en) * | 1940-01-02 | 1941-05-13 | Evertz Matthew | Therapeutic agent and food from watermelons |
| KR20050080480A (en) * | 2004-02-09 | 2005-08-12 | 주식회사 태평양 | Cosmetic composition for inflammation in skin containing citrullis vulgaris extract |
| WO2005105126A1 (en) * | 2004-04-30 | 2005-11-10 | National University Corporation NARA Institute of Science and Technology | Active oxygen eliminator and moisturizer containing wild watermelon extract |
| JP2012106955A (en) * | 2010-11-18 | 2012-06-07 | Akita Univ | Physiologically active composition, food product and medicinal agent for prevention of hypertension, and methods for manufacturing them |
| CN104622938A (en) * | 2014-12-09 | 2015-05-20 | 石河子大学 | Citrullus lanatus.convar megulaspemus (L.) skin extract and medical application and preparation method of composition |
| JP2016175861A (en) * | 2015-03-19 | 2016-10-06 | 株式会社ユーグレナ | Epidermal turnover accelerator, skin collagen production accelerator, and skin cosmetic |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100358488C (en) * | 2005-05-18 | 2008-01-02 | 安徽华夏养生学术研究所 | Whitening crystal invisual face film for activating skin and production thereof |
-
2017
- 2017-06-19 TW TW106120420A patent/TWI637747B/en not_active IP Right Cessation
-
2018
- 2018-05-30 CN CN201810542075.0A patent/CN109125377A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2242062A (en) * | 1940-01-02 | 1941-05-13 | Evertz Matthew | Therapeutic agent and food from watermelons |
| KR20050080480A (en) * | 2004-02-09 | 2005-08-12 | 주식회사 태평양 | Cosmetic composition for inflammation in skin containing citrullis vulgaris extract |
| WO2005105126A1 (en) * | 2004-04-30 | 2005-11-10 | National University Corporation NARA Institute of Science and Technology | Active oxygen eliminator and moisturizer containing wild watermelon extract |
| JP2012106955A (en) * | 2010-11-18 | 2012-06-07 | Akita Univ | Physiologically active composition, food product and medicinal agent for prevention of hypertension, and methods for manufacturing them |
| CN104622938A (en) * | 2014-12-09 | 2015-05-20 | 石河子大学 | Citrullus lanatus.convar megulaspemus (L.) skin extract and medical application and preparation method of composition |
| JP2016175861A (en) * | 2015-03-19 | 2016-10-06 | 株式会社ユーグレナ | Epidermal turnover accelerator, skin collagen production accelerator, and skin cosmetic |
Non-Patent Citations (4)
| Title |
|---|
| MEE YOUNGHONG 等: "Watermelon consumption improves inflammation and antioxidant capacity in rats fed an atherogenic diet", 《NUTRITION RESEARCH》 * |
| 于志瀛等: "《药学服务技术》", 30 November 2015, 中国轻工业出版社 * |
| 樊蔚虹: "《高血压饮食养生宝典》", 31 May 2013, 山西科学技术出版社 * |
| 程志强: "西瓜果实中几种功能性成分研究", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151830A (en) * | 2019-05-27 | 2019-08-23 | 嘉兴市爵拓科技有限公司 | Water melon young fruit and Garbo melon young fruit are used to prepare the purposes of the medical composition of controlling gene |
| CN112007036A (en) * | 2019-05-29 | 2020-12-01 | 百岳特生物科技（上海）有限公司 | Application of compound and composition thereof in preparing medicine for relieving lung cell inflammation activity |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI637747B (en) | 2018-10-11 |
| TW201904600A (en) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102292093B (en) | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome | |
| Campisi et al. | Cell senescence: role in aging and age-related diseases | |
| Suttisuwan et al. | Isolation and characterization of anti-inflammatory peptides derived from trypsin hydrolysis of microalgae protein (Synechococcus sp. VDW) | |
| Tur et al. | Diet and pemphigus: in pursuit of exogenous factors in pemphigus and fogo selvagem | |
| Yu et al. | Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage | |
| CN106074468B (en) | Cinnamic acid can induce the purposes in vegf expression and the inducer of secretion in preparation | |
| CN109125377A (en) | Application of watermelon young fruit and jaboticaba young fruit in preparation of pharmaceutical composition for regulating and controlling genes | |
| KR101791206B1 (en) | The onion juice and method of it | |
| Mirakzehi et al. | The effects of hydroalcoholic extracts of Withania somnifera root, Withania coagulans fruit and 1, 25-dihydroxycholecalciferol on immune response and small intestinal morphology of broiler chickens | |
| Leung | 10 To Build or to Transform Vegetarian China | |
| JP2005060308A (en) | Agent for enhancing and promoting production of adiponectin | |
| TW202003008A (en) | Use of banana stamen extracts for preparing a pharmaceutical composition for promoting hair growth | |
| Zinina et al. | Protein hydrolysate as a source of bioactive peptides in diabetic food products | |
| Lim et al. | Blood pressure-lowering effects of alacalase-hydrolyzed camellia seed hull in vitro and in spontaneous hypertensive rats | |
| Ayaz et al. | Effect of Green Tea on Blood Pressure in Healthy Individuals: A Meta-Analysis | |
| Verma et al. | Therapeutic Potential of Nutritional Food for a Healthy Cardiometabolic System-A Review of Molecular Mechanism | |
| CN106511970B (en) | Application of the rHDL in treatment hypertensive disorder in pregnancy | |
| CN1940048B (en) | Soybean peptide raw wine and its production | |
| TWI607755B (en) | Uses of ergostatrien-3β-ol | |
| TWI589297B (en) | Use of melon leaf extract for the treatment and / or prevention of alcoholic fatty liver or its complications | |
| CN111617218A (en) | Fat burning fermentation product, preparation method thereof and application of fat burning fermentation product in preparation of fat burning weight reducing composition | |
| Serra-Majem et al. | Recognition of the Mediterranean diet: going a step further | |
| Ortega et al. | Antihyperglycemic, Hypoglycemic, and Lipid-Lowering Effect of Peptide Fractions of M. pruriens L. in an Obese Rat Model | |
| CN108175014A (en) | A kind of preparation method of artemisia selengensis ferment composite beverage | |
| Bassey Etim et al. | Ameliorative Effect of Aqueous Extract of Tetracarpidium Conophorum (African Walnut on Salt Induced Hypertensive Wistar Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200618 Address after: No. 989, Jinge Road, Jinshan Industrial Zone, Jinshan District, Shanghai Applicant after: Bayote Biotechnology (Shanghai) Co.,Ltd. Address before: Taipei City, Taiwan, China Applicant before: TCI Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190104 |
|
| WD01 | Invention patent application deemed withdrawn after publication |